These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 19564272

  • 1. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
    Winterstein AG, Gerhard T, Shuster J, Saidi A.
    Pediatrics; 2009 Jul; 124(1):e75-80. PubMed ID: 19564272
    [Abstract] [Full Text] [Related]

  • 2. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A.
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [Abstract] [Full Text] [Related]

  • 3. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.
    Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S.
    N Engl J Med; 2019 Mar 21; 380(12):1128-1138. PubMed ID: 30893533
    [Abstract] [Full Text] [Related]

  • 4. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
    Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, Marcus SC.
    J Am Acad Child Adolesc Psychiatry; 2012 Feb 21; 51(2):147-56. PubMed ID: 22265361
    [Abstract] [Full Text] [Related]

  • 5. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC.
    Arch Pediatr; 2014 Jan 21; 21(1):108-12. PubMed ID: 24309201
    [Abstract] [Full Text] [Related]

  • 6. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 21; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 7. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B.
    Pediatrics; 2006 Sep 21; 118(3):e704-10. PubMed ID: 16950962
    [Abstract] [Full Text] [Related]

  • 8. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children.
    Suarez EA, Bateman BT, Hernandez-Diaz S, Straub L, McDougle CJ, Wisner KL, Gray KJ, Pennell PB, Lester B, Zhu Y, Mogun H, Huybrechts KF.
    JAMA Psychiatry; 2024 May 01; 81(5):477-488. PubMed ID: 38265792
    [Abstract] [Full Text] [Related]

  • 9. Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium.
    Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K, Gissler M, Hernandez-Diaz S, Karlsson P, Karlstad Ø, Kieler H, Lahesmaa-Korpinen AM, Mogun H, Nørgaard M, Reutfors J, Sørensen HT, Zoega H, Bateman BT.
    JAMA Psychiatry; 2018 Feb 01; 75(2):167-175. PubMed ID: 29238795
    [Abstract] [Full Text] [Related]

  • 10. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options.
    Hodgkins P, Shaw M, Coghill D, Hechtman L.
    Eur Child Adolesc Psychiatry; 2012 Sep 01; 21(9):477-92. PubMed ID: 22763750
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M, Dahl AA, Martinsen EW, Klungsøyr O, Haavik J, Peleikis DE.
    Eur Neuropsychopharmacol; 2014 Dec 01; 24(12):1873-84. PubMed ID: 25453480
    [Abstract] [Full Text] [Related]

  • 12. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun 01; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 13. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
    Janols LO, Liliemark J, Klintberg K, von Knorring AL.
    Nord J Psychiatry; 2009 Nov 01; 63(6):508-16. PubMed ID: 19958258
    [Abstract] [Full Text] [Related]

  • 14. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
    Frölich J, Banaschewski T, Spanagel R, Döpfner M, Lehmkuhl G.
    Z Kinder Jugendpsychiatr Psychother; 2012 Sep 01; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
    [Abstract] [Full Text] [Related]

  • 15. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
    Barner JC, Khoza S, Oladapo A.
    Curr Med Res Opin; 2011 Sep 01; 27 Suppl 2():13-22. PubMed ID: 21973228
    [Abstract] [Full Text] [Related]

  • 16. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN, Wilde AA.
    Ned Tijdschr Geneeskd; 2006 Aug 05; 150(31):1713-4. PubMed ID: 16924941
    [Abstract] [Full Text] [Related]

  • 17. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR.
    J Child Adolesc Psychopharmacol; 2009 Oct 05; 19(5):501-10. PubMed ID: 19877974
    [Abstract] [Full Text] [Related]

  • 18. [Supervised off-label prescribing of methylphenidate in adult ADHD].
    Carton L, Dondaine T, Deheul S, Marquié C, Brigadeau F, Amad A, Devos D, Danel T, Bordet R, Cottencin O, Gautier S, Ménard O.
    Encephale; 2019 Feb 05; 45(1):74-81. PubMed ID: 30122296
    [Abstract] [Full Text] [Related]

  • 19. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.
    Lurie S, O'Quinn A.
    J Neuropsychiatry Clin Neurosci; 1991 Feb 05; 3(1):41-50. PubMed ID: 7580171
    [Abstract] [Full Text] [Related]

  • 20. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS.
    Drugs Today (Barc); 2013 Oct 05; 49(10):647-65. PubMed ID: 24191257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.